Our science is just one way we champion patients. We believe in setting up a support system for patients and families that responds to not only their physical needs, but also their mental and emotional needs for well-rounded health. From raising disease awareness to funding research, our network uncovers hope.
See our progress
Follow our product candidates on their journeys to fighting serious diseases.
Spinal Muscular Atrophy
In partnership with Gilead Sciences
“We focus on the patients here; they’re the reason we’re at Scholar Rock.”
Senior Director, IT
We focus on the discovery and development of safe and effective therapies to find optimal solutions for those who need it.
How it Works
A clinical trial is a type of research involving human volunteers (also called participants) that follow strict protocols to evaluate whether a new drug is safe and effective in people. Clinical trials are usually conducted in multiple phases, each of which are designed to answer specific scientific questions. Data from these studies are then submitted to regulatory agencies, (e.g. US Food & Drug Administration), to gain approval of the new drug or treatment.
Find the safest dose
Test for beneficial effects and undesirable effects
Monitor adverse reactions
Test long term safety, in a diverse patient population
Focus on the study drug’s safety and tolerability. Phase 1 trials evaluate multiple doses in a small number of individuals that are, often, healthy volunteers.
Focus on the study drug’s safety and efficacy in patients with the disease or condition being studied. If a study drug is found to be reasonably safe in Phase 1 trials, it will then be investigated in Phase 2.
Focus on the study drug’s safety and efficacy, oftentimes compared to standard-of-care or control groups. Phase 3 trials typically evaluate much larger numbers of patients and follow the most rigorous protocols of the different phases. A study drug that passes Phase 3 can be submitted to regulatory agencies for approval to be marketed to the general public.
Pursue ongoing evaluation and monitor the study drug in patients, even after receiving regulatory approval.
Expanded Access Policy
As we advance our investigational therapies through clinical development, our goal is to provide access to these therapies at the appropriate time and in the correct manner for patients.
November 30, 2021
Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
November 12, 2021
Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B
November 9, 2021
Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress